Month: April 2022

FirstFarms A/S has, as previously announced in company announcement no. 23/2021, entered into agreement to acquire 100% of the Hungarian company Try-Béta Kft. regarding land leases and crop production, silo plant and machinery. The purchase price is 26 mDKK. The purchase agreement is conditional to final due diligence and authority approvals, and the transaction is now expected to be finalised at the latest in Q3 2022. With the acquisition, FirstFarms significantly supports and expands its operations in Hungary. The company takes over the operation of 1,600 hectares of cultivated land (wheat, barley, maize, rape seed and sunflower), 6,900 tons of storage and silo capacity and full machinery. Try-Béta’s 15 employees continue their work, but as employees of FirstFarms. “This is a reasonable trade with great importance for the...

SHANGHAI, China, April 25, 2022 (GLOBE NEWSWIRE) — Bilibili Inc. (“Bilibili” or the “Company”) (NASDAQ: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the Securities and Exchange Commission on April 25, 2022. The annual report can be accessed on the Company’s investor relations website at http://ir.bilibili.com. The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to Investor Relations Department, Bilibili Inc., Building 3, Guozheng Center, No. 485 Zhengli Road, Yangpu District, Shanghai, 200433, People’s Republic...

NORTHBROOK, Ill., April 25, 2022 (GLOBE NEWSWIRE) — Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the pricing of its underwritten public offering of (i) units consisting of 26,680,720 shares of its common stock and accompanying Class A warrants to purchase up to 26,680,720 shares of its common stock and (ii) units consisting of pre-funded warrants to purchase up to 590,000 shares of common stock and accompanying Class A warrants to purchase up to 590,000 shares of common stock. Each share of common stock (or pre-funded warrant) is being sold together with one Class A warrant at a combined purchase price of $1.10 per unit (or $1.10 (less) $0.001 (the exercise...

ProVen VCT plcProVen Growth and Income VCT plc 25 April 2022 Extension of 2022/2023 Offer On 11 January 2022, ProVen VCT plc and ProVen Growth and Income VCT plc (the “Companies”) launched offers for subscription (the “Offer”) to raise up to £40.0 million by way of an issue of new ordinary shares (“New Ordinary Shares”) in the Companies, with each of the Companies raising up to £20.0 million, together with an over-allotment facility of up to a further £40.0 million (being up to £20.0 million for each of the Companies). Full details of the Offer are contained in a prospectus (comprising a Securities Note, Registration Document and Summary (the “Prospectus”)), which was published by the Companies on 11 January 2022. The boards of each of the Companies are pleased to announce that the 2022/23 Offer for each of the Companies...

SOMERSET, N.J., April 25, 2022 (GLOBE NEWSWIRE) — CareCloud, Inc. (formerly MTBC, Inc., or the “Company”) (Nasdaq: MTBC, MTBCO, MTBCP), a leader in healthcare technology solutions for medical practices and health systems nationwide, will release its financial results for the first quarter ended March 31, 2022 before the market opens on Monday, May 9, 2022. The Company will follow with a conference call for investors at 8:30 a.m. Eastern Time. The live webcast of the conference call and related presentation slides can be accessed at ir.carecloud.com/events. An audio-only option is available by dialing 1-201-389-0920 and referencing “CareCloud First Quarter 2022 Earnings Call.” Investors who opt for audio-only will need to download the related slides at ir.carecloud.com/events. A replay of the conference call and related...

To give a new impetus to the renovation of apartment buildings, the SB Modernization Fund established by Šiaulių Bankas has started operations. Loans to the EUR 275 million Fund  were provided to the fund by Lithuanian and foreign financial institutions. SB modernizavimo fondas, UAB, a subsidiary of Šiaulių Bankas, has signed agreements with the European Investment Bank (EIB), the Council of Europe Development Bank (CEB), Nordic Investment Bank (NIB), INVL Asset Management, Swedbank and Šiaulių Bankas. The 275-million-euro fund administered by Šiaulių Bankas will consist not only of investors, but also of the Lithuanian state and the European Structural and Investment Fund (ESIF). “Investors focused on the newly established fund are ready to accelerate the renovation apartment buildings. We have set ourselves the ambitious goal of...

Reno, Nev., April 25, 2022 (GLOBE NEWSWIRE) — American Battery Technology Company (ABTC) (OTCQB: ABML), an American critical minerals and lithium-ion battery recycling company, today announced the appointment of Kimberly Eckert as its new Chief Financial Officer.  Eckert has over two decades of corporate finance and strategic mineral resource development experience, working specifically within the critical minerals and precious metals industry, across the investment banking, corporate financial management, investment management, and strategic consulting fields. Eckert served as Vice President at Deutsche Bank in Global Corporate Investment Banking of its Natural Resources Metals & Mining group.  There, she managed a team of analysts and associates to provide strategic and transaction services to metals and mining companies...

LOS ANGELES, CA, April 25, 2022 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB:ENDV) today announced an agreement with NAMSA – a leading Global Contract Research Organization (CRO) and medical device reimbursement specialist – as strategic advisors to develop in-patient and out-patient medical reimbursement strategies for Endonovo’s flagship PEMF (Pulsed Electro-Magnetic Field) product SofPulse®. “Engaging NAMSA as strategy advisors to develop and apply proven medical device reimbursement strategies is a huge advantage for Endonovo and our shareholders, according to Endonovo CEO Alan Collier. “NAMSA is a proven medical device development partner with relevant therapeutic know-how that is critical when seeking acceleration of reimbursement efforts and commercialization objectives,” he pointed out. NAMSA was founded in 1967...

Bethesda Row Marks the 16th Retail Location for Omnichannel Jewelry Leader, Just in Time for Wedding Season SAN FRANCISCO, April 25, 2022 (GLOBE NEWSWIRE) — Brilliant Earth Group, Inc. (“Brilliant Earth” or the “Company”) (Nasdaq: BRLT), an innovative, digital-first jewelry company and global leader in ethically sourced fine jewelry, today announced its newest showroom opening in Bethesda, Maryland. This marks the sixteenth showroom for Brilliant Earth and advances the Company’s initiative to deliver an omnichannel experience to consumers nationally. As the second location for the greater D.C. metro area, the Company’s showrooms complement its innovative digital channels, which together allow customers to shop for jewelry how, when and where they want, and in a way that transitions seamlessly between an online and in-person shopping...

STOCKHOLM, SWEDEN, April 25, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company OssDsign has enrolled all patients in the clinical study TOP FUSION, which will primarily evaluate the safety and efficacy of OssDsign Catalyst in patients undergoing spinal fusion surgery. OssDsign will now follow the patients recruited for the study for 24 months. The outcome of the study will primarily focus on healing between the vertebrae and the lack of treatment-related side effects. The company’s nanosynthetic bone graft OssDsign Catalyst received FDA approval in 2020 and was launched on the US market in August 2021. “OssDsign builds a comprehensive package of clinical data for OssDsign Catalyst, now with a fully recruited TOP FUSION study. The study will generate important clinical information...